Leveraging the Treg-intrinsic CTLA4–PKCη signaling pathway for cancer immunotherapy
Enregistré dans:
Auteurs principaux: | Hsin-Yu Liu, Christophe Pedros, Kok-Fai Kong, Ann J Canonigo-Balancio, Wen Xue, Amnon Altman |
---|---|
Format: | article |
Langue: | EN |
Publié: |
BMJ Publishing Group
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/6b0727518baf4f5588b97fc3c4c8adbd |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Molecular insight into isoform specific inhibition of PI3K-α and PKC-η with dietary agents through an ensemble pharmacophore and docking studies
par: Baki Vijaya Bhaskar, et autres
Publié: (2021) -
Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy
par: Clayton Hardman, et autres
Publié: (2020) -
Sublingual immunotherapy increases Treg/Th17 ratio in allergic rhinitis
par: Wang Jiarong, et autres
Publié: (2021) -
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas
par: Zohreh Amoozgar, et autres
Publié: (2021) -
Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10.
par: Anna Maria Riccio, et autres
Publié: (2012)